SHILPAMED

Shilpa Medicare Share Price

 

 

Invest in Shilpa Medicare with 2.03X leverage

Invest with MTF

Performance

  • Low
  • ₹309
  • High
  • ₹318
  • 52 Week Low
  • ₹260
  • 52 Week High
  • ₹500
  • Open Price₹312
  • Previous Close₹313
  • Volume171,237
  • 50 DMA₹312.29
  • 100 DMA₹337.13
  • 200 DMA₹356.83

Investment Returns

  • Over 1 Month -1.22%
  • Over 3 Month -11.64%
  • Over 6 Month -25.71%
  • Over 1 Year -13.39%

Smart Investing Starts Here Start SIP with Shilpa Medicare for Steady Growth!

Invest Now

Shilpa Medicare Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 45
  • PEG Ratio
  • 0.4
  • Market Cap Cr
  • 6,178
  • P/B Ratio
  • 2.6
  • Average True Range
  • 15.39
  • EPS
  • 7.91
  • Dividend Yield
  • 0.2
  • MACD Signal
  • -9.5
  • RSI
  • 62.27
  • MFI
  • 78.24

Shilpa Medicare Financials

Shilpa Medicare Technicals

EMA & SMA

Current Price
₹315.90
+ 2.8 (0.89%)
pointer
  • Bearish Moving Average 5
  • Bullish Moving Average 11
  • 20 Day
  • ₹295.04
  • 50 Day
  • ₹312.29
  • 100 Day
  • ₹337.13
  • 200 Day
  • ₹356.83

Resistance and Support

314.23 Pivot Speed
  • R3 328.87
  • R2 323.43
  • R1 319.67
  • S1 310.47
  • S2 305.03
  • S3 301.27

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Shilpa Medicare Ltd. is a leading Indian pharmaceutical company specializing in the development and manufacturing of generic drugs, APIs, and biotechnology products. Focused on oncology and other therapeutic areas, it aims to provide affordable healthcare solutions globally.

Shilpa Medicare Limited has an operating revenue of Rs. 1,341.55 Cr. on a trailing 12-month basis. An annual revenue growth of 13% is good, Pre-tax margin of 10% is healthy, ROE of 3% is fair but needs improvement. The company has a reasonable debt to equity of 10%, which signals a healthy balance sheet. The stock from a technical standpoint is trading below to its 200DMA and close to its 50DMA. It needs to take out the 200DMA levels and stay above it to make any further meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 73 which is a FAIR score but needs to improve its earnings, a RS Rating of 44 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at B- which is evident from recent demand for the stock, Group Rank of 75 indicates it belongs to a poor industry group of Medical-Diversified and a Master Score of C is fair but needs to improve. Overall, the stock has mediocre earnings and technical strength, there are superior stocks in the current market environment.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Shilpa Medicare Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2026-02-06 Quarterly Results
2025-11-13 Quarterly Results
2025-08-13 Quarterly Results
2025-05-26 Audited Results & Final Dividend
2025-02-10 Quarterly Results
Date Purpose Remarks
2025-09-17 FINAL Rs.1.00 per share(100%)Final Dividend
View Shilpa Medicare Dividend History Arrow
Date Purpose Remarks
2025-10-03 Bonus Re.0.00 issue of equity shares in the ratio of 1:1 of Re. 1/-. (RD date revised)

Shilpa Medicare F&O

Shilpa Medicare Shareholding Pattern

40.13%
5.2%
1.79%
10.97%
27.8%
14.11%

About Shilpa Medicare

  • NSE Symbol
  • SHILPAMED
  • BSE Symbol
  • 530549
  • Managing Director
  • Mr. Vishnukant C Bhutada
  • ISIN
  • INE790G01031

Similar Stocks to Shilpa Medicare

Shilpa Medicare FAQs

Shilpa Medicare share price is ₹315 As on 06 February, 2026 | 03:11

The Market Cap of Shilpa Medicare is ₹6178.4 Cr As on 06 February, 2026 | 03:11

The P/E ratio of Shilpa Medicare is 45 As on 06 February, 2026 | 03:11

The PB ratio of Shilpa Medicare is 2.6 As on 06 February, 2026 | 03:11

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23